Pantop%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520ds

# Pantoprazole ## Overview Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system in gastric parietal cells. ## Primary Indications * Healing of erosive esophagitis associated with gastroesophageal reflux disease (GERD). * Maintenance of healing of erosive esophagitis. * Reduction of risk of NSAID-associated gastric ulcers in patients needing continuous NSAID treatment. * Pathological hypersecretory conditions, including Zollinger-Ellison syndrome (ZES). ## Adult Dosing * **Healing of Erosive Esophagitis:** 40 mg orally once daily for up to 8 weeks. * **Maintenance of Healing of Erosive Esophagitis:** 40 mg orally once daily. * **Reduction of Risk of NSAID-Associated Gastric Ulcers:** 20 mg orally once daily. * **Pathological Hypersecretory Conditions (e.g., ZES):** 40 mg orally twice daily. Doses may be increased as needed. Doses greater than 240 mg daily should be administered intravenously. The maximum recommended intravenous dose is 40 mg every 8 hours. ## Pediatric Dosing Dosing in pediatric patients is highly variable and depends on indication and weight. Refer to specific pediatric guidelines or product labeling for detailed information. * **Erosive Esophagitis (1-5 years):** 10 mg orally once daily for up to 8 weeks. * **Erosive Esophagitis (5-16 years):** 20 mg orally once daily for up to 8 weeks. * **Erosive Esophagitis (≥17 years):** 40 mg orally once daily for up to 8 weeks. ## Dose Adjustments * **Hepatic Impairment:** A maximum daily dose of 20 mg orally should not be exceeded in patients with severe hepatic impairment. ## Contraindications * Known hypersensitivity to pantoprazole or any component of the formulation. ## Adverse Effects Common adverse effects include headache, diarrhea, nausea, abdominal pain, vomiting, dizziness, and flatulence. Long-term use may be associated with increased risk of fractures (hip, wrist, spine), Clostridium difficile infection, vitamin B12 deficiency, and hypomagnesemia. ## Key Drug Interactions * **Drugs dependent on gastric pH for absorption:** PPIs can decrease absorption of drugs like ketoconazole, itraconazole, and certain HIV protease inhibitors. * **Methotrexate:** PPIs may increase methotrexate levels, potentially leading to toxicity. * **CYP2C19 substrates:** Pantoprazole is a moderate inhibitor of CYP2C19. Caution is advised when co-administered with drugs metabolized by this enzyme (e.g., clopidogrel, voriconazole). ## Monitoring * Monitor for signs and symptoms of fractures, C. difficile infection, vitamin B12 deficiency, and hypomagnesemia, especially with long-term use. * Monitor electrolytes, particularly magnesium, in patients on long-term therapy or receiving concomitant medications like digoxin or diuretics. ## Clinical Pearls * Pantoprazole is available in oral and intravenous formulations. * Oral pantoprazole should be taken at least 1 hour before a meal. * Do not crush or chew delayed-release tablets or capsules. * Long-term use of PPIs should be re-evaluated regularly, and the lowest effective dose should be used. *** **Disclaimer:** This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information and relevant clinical guidelines before making therapeutic decisions.